Monday, November 22, 2021

Pull Incentives at ASM/ESCMID

›
  On a personal note, as I grow older, I find I am likely to be more dependent on physicians and caregivers.  I am grateful to have a truly ...
Monday, October 11, 2021

Europe, Antibacterials, Pull Incentives and Access

›
      Without a significant pull incentive, our pipeline of new antibacterials is doomed. This must be our top priority. If a significant pu...
Tuesday, October 5, 2021

Empiric broad spectrum antimicrobial therapy is here to stay.

›
  Recent discussions on the economics of innovation in rapid diagnostic testing for bacterial infections in the hospital setting have inspir...
Monday, April 26, 2021

Antibiotic Strategies for Success - A Bridge to Nowhere?

›
  This blog was inspired by a recent conversation with a CEO of a clinical phase antibiotic biotech. Among other things, we pursued a discus...
2 comments:
Monday, April 5, 2021

Pull American - Why Not?

›
  In a sleepy moment I had an inspiration. Funding a pull incentive for antibiotic R&D in the US (like a market entry reward for example...
1 comment:
Friday, March 12, 2021

The Pew Trust Analysis of the Antibacterial Pipeline

›
  The Pew Charitable Trust just posted their analysis of the antibacterial pipeline.     They provide two separate analyses, one for   antib...
Monday, February 15, 2021

Pull Incentives and AMR - Is Europe up to the Task?

›
  I have been saying for years that for a pull incentive to actually function as an incentive, it must be large enough to motivate investors...